Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAngioSoma Inc

AngioSoma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
300000
Market Cap
0.12M

Momentum Score

…

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosure about AngioSoma Inc (GSTC.PK) is limited, and the company does not provide clear, verifiable information about its core business, products, or financial condition. Potential long-term growth drivers are therefore unclear; investors may be attracted only by speculative upside should management later disclose viable assets, secure partnerships, or achieve operational milestones.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.00M
Debt / Equity
-0.26
ROE
-
Net Debt
0.36M
ROCE
88.36%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Income before tax -1.49M -1.49M -1.49M -1.49M -9.80M
Net income -1.49M -1.49M -1.64M -1.49M -9.67M
Selling general administrative 1.27M 1.27M 1.27M 1.26M 9.09M
Selling and marketing expenses - 0.60M - - -
Gross profit - 0.00M 0.00M 0.00M -0.00M
Reconciled depreciation - - 0.00M 0.00M 0.00M
Ebit -1.27M -1.27M -1.27M -1.27M -9.09M
Ebitda -1.27M -1.27M -1.42M -1.26M -9.51M
Depreciation and amortization 0.00M 0.00M -0.15M 0.00M -0.42M
Operating income -1.27M -1.27M -1.27M -1.26M -9.09M
Other operating expenses 1.27M 1.27M 1.27M 1.26M 9.09M
Interest expense 0.07M 0.07M 0.07M 0.07M 0.29M
Net interest income - -0.09M -0.07M -0.07M -0.29M
Income tax expense -0.00M -0.00M 0.15M 0.15M -0.13M
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.27M 1.27M 1.27M 1.26M 9.09M
Cost of revenue - 0.00M 0.00M 0.00M 0.00M
Total other income expense net -0.22M -0.22M -0.22M -0.22M -0.71M
Net income from continuing ops - -1.95M -1.49M -1.49M -9.80M
Net income applicable to common shares - - -1.49M -1.49M -9.80M
Breakdown 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2023-09-30 2022-12-31 2022-09-30 2021-12-31
Total assets - 0.00M 0.01M 0.01M 0.01M
Other current assets - - 0.00M 0.00M -
Total liab 1.43M 1.43M 1.20M 1.20M 0.73M
Total stockholder equity - -1.43M -1.19M -1.19M -0.73M
Other current liab 0.86M 0.74M 0.80M 0.80M 0.40M
Common stock 1.00M 1.00M 0.72M 0.72M 0.56M
Capital stock - 1.00M 0.72M 0.72M 0.56M
Retained earnings -20.45M -20.45M -18.50M -18.50M -17.02M
Cash - 0.00M 0.01M 0.01M 0.01M
Total current liabilities 1.43M 1.43M 1.20M 1.20M 0.73M
Current deferred revenue -0.11M -0.11M 0.00M 0.00M -
Net debt 0.36M 0.37M 0.01M 0.01M 0.10M
Short term debt 0.36M 0.37M 0.02M 0.02M 0.11M
Short long term debt - 0.36M 0.02M 0.02M 0.17M
Short long term debt total 0.36M 0.37M 0.02M 0.02M 0.11M
Other stockholder equity 19.46M 18.02M 16.59M 16.58M 15.73M
Total current assets - 0.00M 0.01M 0.01M 0.01M
Net tangible assets - - -1.20M -1.20M -0.73M
Inventory - - - - 0.00M
Accounts payable 0.33M 0.33M 0.38M 0.38M 0.22M
Accumulated other comprehensive income -1.43M 0.00M - 0.01M -
Non current assets total - 0.00M 0.00M 0.00M 0.00M
Breakdown 2023-09-30 2022-12-31 2022-09-30 2021-12-31 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-12-31 2022-09-30 2021-12-31 2021-09-30
Investments - - - 0.00M 0.00M
Change to liabilities - 0.43M 0.43M 0.20M 0.20M
Net borrowings 0.06M 0.01M 0.01M 0.10M 0.10M
Total cash from financing activities 0.20M 0.33M 0.33M 0.68M 0.68M
Change to operating activities - 0.01M 0.01M 0.02M 0.02M
Net income -1.95M -1.49M -1.49M -9.80M -9.80M
Change in cash -0.01M 0.00M 0.00M -0.08M -0.08M
Begin period cash flow 0.01M 0.01M 0.01M 0.08M 0.08M
End period cash flow 0.00M 0.01M 0.01M 0.01M 0.01M
Total cash from operating activities -0.21M -0.33M -0.33M -0.75M -0.75M
Issuance of capital stock 0.15M 0.32M 0.32M 0.58M 0.58M
Depreciation 0.03M 0.05M 0.05M 0.00M 0.00M
Change to inventory - - - 0.00M 0.00M
Other cashflows from financing activities 0.07M 0.32M 0.32M 0.18M 0.08M
Change to netincome - 0.66M 0.66M 8.55M 8.55M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.45M 0.44M 0.44M 0.22M 0.22M
Stock based compensation 1.27M 0.51M 0.51M 8.13M 8.13M
Other non cash items 0.06M 0.15M 0.15M 0.69M 0.69M
Free cash flow -0.21M -0.33M -0.33M -0.75M -0.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GSTC
AngioSoma Inc		 -
-%		 0.00 - - 78200.54 - 124103.10 -0.97
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

AngioSoma Inc

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.

1280 Lexington Avenue, New York, NY, United States, 10028

509-531-1671

https://www.globestartherapeutics.com

Name Title Year Born
Mr. James C. Katzaroff Pres, CEO, Sec., Principal Exec. Officer & Chairman 1957
Mr. Robert Hale Chicoski CPA CFO, Treasurer & Principal Financial Officer 1943
Mr. William J. Farley B.Sc. Devel. Officer & Director 1955
Mr. Steven F. Penderghast Commercial Officer & Director NA
Ms. Brooke Greenwald Chief Marketing Officer NA
Mr. David Croom Exec. VP NA
Mr. James C. Katzaroff President, CEO, Secretary, Principal Executive Officer & Chairman of the Board 1957
Mr. David Croom Executive Vice President NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…